Clearmind Medicine (NASDAQ:CMND) Trading Down 1.6% – Here’s What Happened

Clearmind Medicine Inc. (NASDAQ:CMND) shares were down 1.6% on Friday . The company traded as low as $0.52 and last traded at $0.52. Approximately 262,552 shares were traded during trading, a decline of 98% from the average daily volume of 12,822,764 shares. The stock had previously closed at $0.5286.

Clearmind Medicine Stock Performance

The firm has a market cap of $780,000.00, a P/E ratio of -0.03 and a beta of 0.87. The firm’s fifty day moving average price is $0.84 and its 200 day moving average price is $4.91.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($3.32) EPS for the quarter.

Institutional Investors Weigh In On Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC grew its holdings in Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 224,378 shares of the company’s stock after purchasing an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned approximately 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 96.05% of the company’s stock.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.